Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

  • Name

    Bristol-Myers Squibb Company

  • CEO

    Dr. Christopher S. Boerner Ph.D.

  • Website

    www.bms.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1887

Profile

  • Market Cap

    $98.51B

  • EV

    $145.56B

  • Shares Out

    2,027.4M

  • Revenue

    $46.51B

  • Employees

    34,100

Margins

  • Gross

    76.18%

  • EBITDA

    40.96%

  • Operating

    19.42%

  • Pre-Tax

    -13.8%

  • Net

    -14.06%

  • FCF

    27.83%

Returns (5Yr Avg)

  • ROA

    2.3%

  • ROTA

    -26.16%

  • ROE

    6.59%

  • ROCE

    10.92%

  • ROIC

    9.63%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $53.34

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $6,653M

  • Net Debt

    $46.99B

  • Debt/Equity

    3.16

  • EBIT/Interest

    5.82

Growth (CAGR)

  • Rev 3Yr

    1.57%

  • Rev 5Yr

    14.28%

  • Rev 10Yr

    11.12%

  • Dil EPS 3Yr

    12.45%

  • Dil EPS 5Yr

    -3.25%

  • Dil EPS 10Yr

    7.18%

  • Rev Fwd 2Yr

    1.7%

  • EBITDA Fwd 2Yr

    0.83%

  • EPS Fwd 2Yr

    -3.59%

  • EPS LT Growth Est

    -5.24%

Dividends

  • Yield

  • Payout

    -73.68%

  • DPS

    $2.37

  • DPS Growth 3Yr

    7.27%

  • DPS Growth 5Yr

    7.77%

  • DPS Growth 10Yr

    5.18%

  • DPS Growth Fwd 2Yr

    4.25%

NYSE:BMY